Science & Nature
The need for diversity in clinical trials is pressing. Breast cancer mortality is 40% higher in Black women diagnosed with the disease than white women, for example. But according to a report compiled by the US Food and Drug Administration’s Center for Drug Evaluation and Research, 80% of clinical trial participants in 2015–2019 were white. Increasing minority representation is necessary to understand whether a drug has different outcomes based on factors such as race, ethnicity, sex and age.
Access options
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
$99.00
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
Rights and permissions
About this article
Cite this article
Amgen pledges $8 million for diversity.
Nat Biotechnol 41, 165 (2023). https://doi.org/10.1038/s41587-023-01698-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-023-01698-8
Read More
Gaylene Buresh